Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates

NCT00677482 | Completed

• 1 other identifier: 7304
• Study Type: observational
• Target: 47
• Locations: 1 country
• Sites: 1

Brief Summary

Cytomegalovirus (CMV) is the most common viral infection in patients who have undergone a transplant.Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. The purpose of this study is to assess how the virus interacts with the patient's immune system, so that in the future it may be possible to develop better ways to prevent and treat the virus infection.

Conditions

Transplant

Keywords

liver transplant; lung transplant; kidney transplant; heart transplant; CMV microRNA

Study Arms (1)

1

Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Solid organ tranplant recipients with both asymptomatic CMV viremia and symptomatic CMV disease are eligible for inclusion in the study. This include liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.

You may qualify if:

• Age \>=18 years
• Solid Organ Transplant Recipients
• Documented CMV disease or asymptomatic CMV viremia

You may not qualify if:

• Unable to comply with protocol

Sponsors & Collaborators

• University of Alberta: lead

Study Sites (1)

University of Alberta Hospital

Edmonton, Alberta, T6G-2E1, Canada

Location

Related Publications (5)

• Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004 Dec;4(12):725-38. doi: 10.1016/S1473-3099(04)01202-2.

  PMID: 15567122 BACKGROUND

• Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005 Feb;5(2):218-27. doi: 10.1111/j.1600-6143.2004.00692.x.

  PMID: 15643981 BACKGROUND

• Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis. 2002 Sep 15;186(6):829-33. doi: 10.1086/342601. Epub 2002 Aug 28.

  PMID: 12198618 BACKGROUND

• Rasmussen L. Molecular pathogenesis of human cytomegalovirus infection. Transpl Infect Dis. 1999 Jun;1(2):127-34. doi: 10.1034/j.1399-3062.1999.010206.x.

  PMID: 11428980 BACKGROUND

• Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, McSharry BP, Morris RJ, Llewellyn-Lacey S, Rickards C, Nomoto A, Sinzger C, Wilkinson GW. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol. 2005 Feb;6(2):181-8. doi: 10.1038/ni1156. Epub 2005 Jan 9.

  PMID: 15640804 BACKGROUND

Study Officials

• Atul Humar, MD

  University of Alberta

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 12, 2008
• First Posted: May 14, 2008
• Study Start: April 1, 2008
• Primary Completion: July 27, 2012
• Study Completion: September 23, 2013
• Last Updated: June 1, 2022

Record last verified: 2015-05

Locations

CA (1)